EUVIMEDEUVIMED entdecken
Crossref

1237-OR: A Novel Hypoglycemic Clamp Procedure to Assess “Spontaneous Time to Recovery” as a Clinically Relevant Safety Endpoint

EVA SVEHLIKOVA, WERNER REGITTNIG, GABRIELE FLUHR, MARTINA URSCHITZ, DANIEL A. KRAUS, THOMAS R. PIEBER

Diabetes · 07.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1237-or ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 07.06.2026. Verfasst von EVA SVEHLIKOVA und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: The conventional hypoglycemic clamp utilizes high-dose IV insulin at fixed rates to induce target hypoglycemia, lacks standardized protocols and results in insulin overdose affecting spontaneous recovery. This improved hypoglycemic clamp procedure adjusts for individual insulin sensitivity and assesses “time to spontaneous recovery” as a critical endpoint.

Methods

12 healthy (41±12 yrs, 28±2 kg/m2) and 12 orally treated T2D subjects (58±4 yrs, 31±5 kg/m2, diabetes duration 9.5±5.6 yrs.) underwent 2 hypoglycemic clamps. After overnight monitoring, hypoglycemia was induced by variable IV insulin at 8:00 am to lower PG from 90 to 70 mg/dL (run-in). This was followed by a PG descent from 70 to 48 mg/dL (induction). At PG 48 mg/dL (nadir) insulin was stopped and glucose administered only if PG drops <48 mg/dL within the first 15 minutes. Time to spontaneous recovery (nadir to PG 70 mg/dl without rescue glucose) was assessed.

Results

47 out of 48 clamps achieved PG nadir and spontaneous recovery (fig.), one clamp was terminated early due to hypoglycemic symptoms. Mean (±SE) recovery time in healthy and T2D subjects was 28±2 and 37±2 min (p<0.01), respectively. Mean (±SE) total insulin dose to achieve nadir was 71±8 mU/kg in healthy and 183±19 mU/kg in T2D subjects (p<0.001).

Conclusion

Our new clamp method safely reaches glucose nadir without rescue glucose, enabling “time to spontaneous recovery” to serve as a safety endpoint for novel therapies. Disclosure E. Svehlikova: None. W. Regittnig: None. G. Fluhr: None. M. Urschitz: None. D.A. Kraus: None. T.R. Pieber: Other - Speaker, Board member, Advisory panel; Current; Arecor. Research Support; Current; AstraZeneca. Other - Research support, Speaker, Board member, Advisory panel; Current; Eli Lilly and Company, Novo Nordisk, Sanofi. Employee; Current; CBmed – Center for Biomarker Research in Medicine. Funding IIS Grant by Eli Lilly (H60-NS-X003)

Zitieren

APA

SVEHLIKOVA, E., REGITTNIG, W., FLUHR, G., URSCHITZ, M., KRAUS, D. A., & PIEBER, T. R. (2026). 1237-OR: A Novel Hypoglycemic Clamp Procedure to Assess “Spontaneous Time to Recovery” as a Clinically Relevant Safety Endpoint. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1237-or

Vancouver

SVEHLIKOVA E, REGITTNIG W, FLUHR G, URSCHITZ M, KRAUS DA, PIEBER TR. 1237-OR: A Novel Hypoglycemic Clamp Procedure to Assess “Spontaneous Time to Recovery” as a Clinically Relevant Safety Endpoint. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1237-or

BibTeX
@article{SVEHLIKOVA2026,
  author = {SVEHLIKOVA, EVA and REGITTNIG, WERNER and FLUHR, GABRIELE and URSCHITZ, MARTINA and KRAUS, DANIEL A. and PIEBER, THOMAS R.},
  title = {1237-OR: A Novel Hypoglycemic Clamp Procedure to Assess “Spontaneous Time to Recovery” as a Clinically Relevant Safety Endpoint},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1237-or}
}
Kostenlos starten →